Clinical Experience with Pulse Dose Rate Brachytherapy for Conservative Treatment of Penile Carcinoma and Comparison with Historical Data of Low Dose Rate Brachytherapy. Issue 7 (July 2015)

• Record Type: Journal Article
• Authors: Kamsu-Kom, L.; Bidault, F.; Mazeron, R.; Baratiny, C.; Martin, V.; Maroun, P.; Dumas, I.; Guemnie-Tafo, A.; Martinetti, F.; Gerbaulet, A.; Chargari, C.; Haie-Meder, C.
• Is Part Of: Clinical oncology. Volume 27:Issue 7(2015)
• Page Start: 387
• Page End: 393
• Publication Date: 2015-07
• Subjects: Oncology -- Periodicals; Tumors -- Periodicals; Cancer -- Treatment -- Periodicals; Radiotherapy -- Periodicals; Neoplasms -- Periodicals; Cancer -- Radiotherapy; Cancer -- Treatment; Oncology; Medical radiology; Radiotherapy; Tumors; Electronic journals; Periodicals; 616.994
• DOI: 10.1016/j.clon.2015.03.010
• Languages: English
• ISSNs: 0936-6555

Abstract

<abstract xml:lang="en" abstract-type="author" id="abs0010"> <title id="sectitle0010">Abstract</title> <sec> <title id="sectitle0015">Aims</title> <p id="abspara0010">To assess the efficacy of pulse dose rate (PDR) interstitial brachytherapy in the treatment of carcinoma of the penis and to compare with historical data of low dose rate (LDR) brachytherapy.</p> </sec> <sec> <title id="sectitle0020">Materials and methods</title> <p id="abspara0015">We reviewed the clinical records of 27 consecutive patients treated in our institution with exclusive PDR brachytherapy for a squamous cell carcinoma of the penis. The median tumour greatest diameter was 20 mm (range: 10–50 mm). Twenty-three patients (85%) had tumours limited to the glans and/or prepuce and four patients (15%) also had inguinal lymph node metastases. Implantations were carried out according to the Paris system and treatments were delivered with PDR brachytherapy.</p> </sec> <sec> <title id="sectitle0025">Results</title> <p id="abspara0020">The median brachytherapy dose was 60 Gy (range: 60–70 Gy). The median treated volume was 28 cm<sup>3</sup> (range: 8–62 cm<sup>3</sup>). The median reference isodose rate was 0.4 Gy/pulse/h (range: 0.4–0.5 Gy/pulse/h). The median number of pulses was 150 (range: 120–175 pulses). With a median follow-up of 33 months (range: 6–64 months), tumour relapses in the penis were reported in four patients (15%). All patients with only local relapse (<italic>n</italic> = 3) were successfully salvaged with partial amputation. The estimated overall survival rate at 3 years was 95% (95% confidence interval: 83–100%). No grade 3 or more acute reaction was observed. Delayed ulcerations and stenoses requiring at least one meatal dilatation were reported in two (9%) and five (22%) patients without local relapse. The treated volume was significantly correlated to the risk of clinically relevant delayed toxicity.</p> </sec> <sec> <title id="sectitle0030">Conclusions</title> <p id="abspara0025">The efficacy/toxicity results of PDR brachytherapy for the treatment of penile carcinoma are comparable with those obtained with LDR brachytherapy in historical cohorts.</p> </sec> </abstract>